Assembly Biosciences Inc (ASMB)
$16.05
+0.05
(+0.31%)▲
Performance
- $15.50$16.50$16.05
3.42%
Downside
Day's Volatility :6.03%
Upside
2.7%
- $7.69$20.04$16.05
52.07%
Downside
52 Weeks Volatility :61.62%
Upside
19.91%
Returns
| Period | Assembly Biosciences Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 15.69% | 0.0% |
6 Months | 8.99% | 0.0% |
1 Year | 82.55% | 0.0% |
3 Years | -59.23% | -20.8% |
Highlights
Market Capitalization | 91.5M |
Book Value | $5.47 |
Earnings Per Share (EPS) | -8.69 |
PEG Ratio | 0.0 |
Wall Street Target Price | 35.5 |
Profit Margin | -212.33% |
Operating Margin TTM | -143.01% |
Return On Assets TTM | -34.72% |
Return On Equity TTM | -101.78% |
Revenue TTM | 21.5M |
Revenue Per Share TTM | 4.13 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -63.9M |
EBITDA | -50.3M |
Diluted Eps TTM | -8.69 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -7.81 |
EPS Estimate Next Year | -6.94 |
EPS Estimate Current Quarter | -2.23 |
EPS Estimate Next Quarter | -2.58 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 121.18%
Technicals Summary
Sell
Neutral
Buy
Assembly Biosciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Assembly Biosciences Inc | -4.48% | 8.99% | 82.55% | -59.23% | -84.26% |
 Regeneron Pharmaceuticals, Inc. | -10.93% | 8.12% | 21.23% | 85.29% | 239.25% |
 Novo Nordisk A/s | -9.85% | -6.35% | 25.79% | 137.8% | 353.05% |
 Alnylam Pharmaceuticals, Inc. | 5.73% | 77.74% | 60.24% | 32.45% | 248.92% |
 Vertex Pharmaceuticals Incorporated | -0.6% | 17.7% | 29.79% | 160.59% | 174.92% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Assembly Biosciences Inc | NA | NA | 0.0 | -7.81 | -1.02 | -0.35 | NA | 5.47 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.04 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 39.53 | 39.53 | 1.79 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.47 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.56 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Assembly Biosciences Inc | Buy | $91.5M | -84.26% | NA | -212.33% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 239.25% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $519.8B | 353.05% | 39.53 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.8B | 248.92% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.8B | 174.92% | 32.84 | -4.74% |
Insights on Assembly Biosciences Inc
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.0% return, outperforming this stock by 92.5%
Institutional Holdings
Armistice Capital, LLC
7.38%Vanguard Group Inc
3.16%Millennium Management LLC
1.95%BlackRock Inc
1.22%Renaissance Technologies Corp
0.87%Geode Capital Management, LLC
0.86%
Company Information
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
Organization | Assembly Biosciences Inc |
Employees | 65 |
CEO | Mr. Jason A. Okazaki |
Industry | Health Technology |
Discover More
Eaton Vance Enh Eqt Inc Ii
$16.05
+0.31%
Aditxt Inc
$16.05
+0.31%
Oportun Financial Corp
$16.05
+0.31%
Yieldmax Tsm Option Income Strategy Etf
$16.05
+0.31%
Innovator International Dvlpd Pwr Bff Etf - August
$16.05
+0.31%
Shoals Technologies Group, Inc.
$16.05
+0.31%
Neos Enhanced Income 1-3 Month T-bill Etf
$16.05
+0.31%
Lakeside Holding Ltd.
$16.05
+0.31%
Allianzim Us Large Cap Buffer20 Nov Etf
$16.05
+0.31%